Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH

    NEXT STORY
    Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
    PREV STORY
    Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Fibrocell Announces Last Patient Visit for Primary Endpoint Analysis in Phase II Clinical Trial of azficel-T for the Treatment of Vocal Cord Scarring

    Primary Endpoint Results Expected in Second Quarter of 2016 Personalized Biologics Pipeline Advancing in ...

    author_avatar
    NASDAQ Market News

    Delcath to Present at Oppenheimer 28th Annual Healthcare Conference

    NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional ...

    author_avatar
    NASDAQ Market News

    Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting

    CAMBRIDGE, Mass., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News